Prostate cancer (PCa) often recurs as incurable castration-resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy. CRPC development relies on androgen receptor (AR) signaling. The IL6/STAT3 pathway is also a key driver of CRPC.
| INTRODUCTION
Prostate cancer (PCa) has the highest incidence of male cancer in Europe and the second highest worldwide. 1 Androgen deprivation therapy (ADT), including drug administration and surgery, has been routines to treat PCa. PCa patients initially are sensitive to ADT. However, in some patients, cancer relapses and progression to even more aggressive castration-resistant prostate cancer (CRPC) eventually occurs. 2 Studies show that most CRPC patients possess high level of androgen receptor (AR) and AR target gene expression, including prostate-specific antigen (PSA). Mutated forms of constitutively active AR splice variants and activated proliferative pathways such as mitogenactivated protein kinase and STAT3 signaling are common. 3, 4 AR protein, which drives CRPC development, consists of several distinct functional domains: a ligand binding domain (LBD), a shorthinge region, a DNA binding domain (DBD), and an amino-terminal domain (NTD). 5 Several AR inhibitors are used clinically or entering clinical phase studies. Abiraterone (Abi) blocks androgen synthesis as a CYP17A1 inhibitor. VT-464 and galeterone (TOK-001) act as lyase inhibitors. Other AR antagonists target the AR LBD, such as enzalutamide (ENZ), ARN-509. 6 However, these AR inhibitors predominantly fail because of mutations in the LBD which create drug resistance. 7 The AR LBD is dispensable for transcriptional activity of AR because its deletion results in the constitutive activation of AR transcription. 8, 9 It is reported that knockdown of full-length AR (AR-FL) in the 22Rv1
and CWR-R1 models does not change the expression of AR target genes or androgen-independent growth. Interestingly, knockdown of truncated AR variants inhibits both. 8, 10, 11 Circulating tumor cells (CTCs) in metastatic CRPC (mCRPC) following ENZ and Abi resistance harbor high AR NTD expression and AR LBD loss according to the Epic Science platform. 12 The strategy to target the AR NTD has potential to overcome resistance to current AR inhibitors that occur due to truncation (AR splice variants) or point mutations of the AR LBD. 6 Constitutively active AR splice variants with mutations in the AR LBD, such as ARv567 and AR-V7, have been found in CRPC patients.
Studies show that ENZ and Abi resistance associates with increasing levels of AR-V7 and ARv567es mutants, in contrast to AR-FL. 13 ARv567es is a constitutively active receptor and contributes to mCRPC progression. 14 As one of the most abundant and best characterized variants among more than 20 already clarified AR splice variants, 14 AR-V7 is suggested to be a predictive marker in primary tumors and as a prognostic factor in CRPC patients. 9 Higher expression of constitutively active AR-V7 was found in CTCs from CRPC patients. 9, 15, 16 The STAT3 pathway is essential to drive PCa progression to mCRPC, integrates with other signaling pathways to reactivate the AR pathway, and regulates interactions between tumor cells and the microenvironment. 17, 18 reported that constitutively active STAT3 induced resistance to ENZ, and the JAK2 inhibitor AG490 could reverse ENZ resistance in LNCaP cells. Thus, it is promising to study STAT3 inhibitors as a therapeutic target for CRPC progression.
Here, we report the small molecule cinobufagin-3-acetate (compound 154 or 154), a natural product isolated from Traditional 
| MATERIALS AND METHODS

| Cell culture and reagents
All the cell lines used in this study are described in Table S1 . ) and were transfected into LNCaP cells as described above.
Our lab has established a fast track androgen receptor response element (ARE) reporter system with an internal normalization system of ARE driven mCherry fluorescent signals. 21 The virus particles were generated by transfecting CS-GS241B-mCHER-Lv207-01 and HIV 
| PSA level detection
The supernatant of LNCaP cells were centrifuged at 12 000g for 1 minute at room temperature, then 0. 
| DARTS assay
LNCaP cell were lysed with cold M-PER buffer (Thermo Fisher Scientific, Pierce cat. no. 78501) containing protease inhibitors (Roche, cat. 
| DNA microarray
This method has been described previously. 19 Total RNA was isolated and tested for RNA integrity by 1% agarose gel electrophoresis, then converted to Cy3-labeled cRNA targets and hybridized to Agilent Whole Human Genome 44k Microarrays (Cat.no. G4845A, Agilent Technologies, Santa Clara, CA). Samples were analyzed by the Agilent Microarray Scanner Bundle. Microarray data were analyzed by J-Express software. 24 We used mean spot signals as intensity measure, normalized the expression data over the entire arrays and log2-transformed and considered genes changed more than 2.0 fold with FDR value <5% as differentially expressed genes. The
ArrayExpress ID for the cell lines is E-MTAB-5102. real-time quantitative PCR (qPCR) were done as described. 19 The
| Immunofluorescence staining
TaqMan assays used for qPCR of human AR (Hs00985639_m1), PSA (Hs00169842_m1), TMPRSS2, and β-actin (Hs99999903_m1) were obtained from Applied Biosystems (Thermo Fisher Scientific).
| Western blot analysis
The levels of expression of phosphorylated STAT3 (Y705), AR, and PSA proteins were determined by western blotting following the procedures described. 25 The following antibodies from Abcam, Cambridge, UK, were used in western blotting: anti-phospho-STAT3
(Tyr705) (ab76315); total STAT3 (ab119352); anti-phospho-STAT1 (Tyr701) (ab30645); total STAT1 (ab119352); β-actin (ab8226); GAPDH (ab181602); FLAG (ab1162); AR V7 (ab198394); TATA binding protein TBP (ab51841); AR (ab133273); PSA (ab53774); and AR N20 (Santa Cruz Biotech, Santa Cruz, CA, sc-816). 
| Co-immunoprecipitation
| Compliance with design and statistical analysis requirements
All experiments were conducted for at least three times. Significance in groups (n = at least 3) was determined by two-tailed Student's t test or statistical analysis of microarrays for microarray data and *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 were considered significant.
The density of each protein band corresponding to its signal intensity was normalized to β-actin or GAPDH and quantified by using the software ImageJ (NIH, Bethesda, MD).
| RESULTS
| Compound 154 is a dual modulator of the IL6/ STAT3 and AR pathways
In a screen of 600 natural compounds, cinobufagin-3-acetate (com- were collected for PSA measurements. All data are represented as the average ± SEM (n = 3). Significance was verified by using unpaired twotailed Student's t test. *P ≤ 0.05 ( Figure 3B ) and 22Rv1 ( Figure 3C ) cells showed that downregulation of AR protein started at 8 hours. Figure 3D shows that 154 treatment did not affect AR mRNA levels in 22Rv1 cells.
Next, we investigated whether the mechanism of AR downregulation by 154 was via an increase in the rate of AR degradation. The MG132 proteasome inhibitor did not prevent protein loss ( Figure 3E ), indicating that the molecular basis for this decline was not increased proteasome-mediated AR degradation. To directly address whether 154 increased the rate of AR degradation in 22Rv1 cells, we used CHX to block new protein synthesis in a pulse-chase assay. However, AR protein half-life in 22Rv1 cells, was not decreased by 154, demonstrating that 154 did not directly enhance AR degradation ( Figure 3F ).
The data suggest that 154 reduced the rate of AR synthesis.
Constitutively active AR splice variants include ARv567es and AR-V7 which are important to CRPC development. We examined and Abi ( Figure 4B ). As shown in Figure 4C , 154 decreased AR-V7 expression in 22Rv1 cells in contrast to ENZ. Thus, 154 selectively inhibits constitutively active AR splice variants ARv567es and AR-V7.
| 154 does not reduce AR nuclear translocation
AR translocation from cytoplasm to nucleus is a key step of AR pathway regulation. 27 To examine if 154 reduces AR nuclear Proteins were detected using the AR-N20 antibody. All data are represented as the average ± SEM (n = 3). Significance was verified by using unpaired two-tailed Student's t test. *P ≤ 0.05, **P ≤ 0.01. Signal intensity was quantified with ImageJ (NIH). FL-AR level was normalized to GAPDH and fold change relative to control was calculated by using FL-AR/ GAPDH ratio. C, 22Rv1 cells were treated with 10 μmol/L enzalutamide, abiraterone, cryptotanshinone or 1 μmol/L 154 in the presence or absence of 1 nmol/L R1881 for 24 h. Proteins were detected using AR-V7 antibody. Signal intensity was quantified with ImageJ (NIH). ARV7 level was normalized to GAPDH and fold change relative to control was calculated by using AR V7/GAPDH ratio chimeric protein encoding amino acids 1-558 of the human AR NTD fused to the Gal4DBD with a reporter gene containing the Gal4-binding site. Androgen and the antiandrogen ENZ have no effect on this chimera due to lack of the AR LBD in the Gal4DBD-AR1-558 This has been illustrated previously 13 and might be associated with drug resistance in mCRPC. Figure 7B shows that 154 treatment lowered the AR NTD signal activity in VCaP cells compared to ENZ, Crypt, or vehicle treatment, consistent with Western blot data.
Taken together, 154 is an AR NTD inhibitor.
| 154 disrupts the association between STAT3 and AR NTD
To directly address if 154 targets AR and STAT3 protein, drug affinity responsive target stability (DARTS) assay was used for target identification which is based on the principle that the targeted protein bound by drugs will be more resistant against proteases. Western blotting showed protection of the target protein AR, whereas digestion of the nontarget proteins STAT3 and β-actin was unchanged by 154. This suggests that 154 targets AR directly ( Figure 8A ).
It is reported that STAT3 interacts with AR NTD at amino acids 234-558 in LNCaP cells after exposure to IL6 for 6 hours. 30 According to our study, 154 inhibited both the IL6/STAT3 and AR pathways.
Based on this, we proposed the hypothesis that the series of changes 
| 154 treatment decreases the ability to form colonies
To determine the antitumor activities of 154, we analyzed its effect in in vitro clonogenic assays. In vitro clonogenic assays correlate well with in vivo assays of tumorigenicity in nude mice. 31 Figure 9A shows that clonogenicity of three cancer lines, DU145, EPT3M1- 
| DISCUSSION AN D CONCLUSIONS
IL6 is a cytokine that activates STAT3 and contributes to growth regulation of several tumors. 32 Overexpression of IL6 was found to correlate with increased metastasis 33 and decreased survival 34 in PCa patients. 17 Constitutively active STAT3 also regulates the progression of PCa and plays a key role in drug resistance, tumor immunoescape, and chemoresistance. 35 Recently, it was summarized that STAT3 is crucial to reactivation of AR, regulates interactions between tumor cells and the microenvironment in CRPC progression. 17 Don-Doncow et al 36 analyzed 223 metastatic samples from 71 CRPC patients and found that 95% of metastases were positive for pSTAT3 and IL6R and with high STAT3 mRNA levels. Therefore, STAT3 is an attractive target for cancer therapy in advanced PCa. One STAT3 inhibitor, Galiellalactone, was reported to remarkably reduce tumor growth and downregulate metastatic spread of PCa cells to lymph nodes. 35 The progression of CRPC relies on AR pathway signaling. 37 Strategies for direct targeting the AR pathway have been thoroughly investigated, including inhibition of AR protein levels or reducing AR nuclear Thus, 154 presents itself as a leading compound for dual inhibition of IL6/STAT3 and AR pathways, thereby providing a promising new PCa treatment modality. The cytotoxicity of 154 is quite high in several different cell lines and the side effect might also be higher in vivo. Thus, modification of 154 will be needed to reduce cytotoxicity. This study also suggests that STAT3 and AR might be active at the same promoters in an association which may serve as a therapeutic target in CRPC.
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F I G U R E 9 154 reduces cell clonogenicity. A, On the 2nd day after seeding, compound 154 was added and DU145, LNCaP, and EPT3M1-STAT3 cells were allowed to grow for 2 weeks to form colonies and next stained with 0.4% crystal violet (w/v). EPT2-D5-miR146a cells were treated with different doses of 154 for 24 h. Fluorescence signals were analyzed by the multi-plate reader (B) and indirect immunofluorescence microscopy analysis (C). All data are represented as the average ± SEM (n = 3). Significance was verified by using unpaired two-tailed Student's t test. *P ≤ 0.05
